Source: Annual Congress 2012 - Sarcoidosis
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. Baughman, D. Culver, F. Cordova, M. Padilla, K. Gibson, E. Lower, P. Engel (Cleveland, Philadelphia, New York, Cincinnati, United States Of America). Bosentan for sarcoidosis associated pulmonary arterial hypertension (BoSAPH) was effective in advanced parenchymal lung disease. Eur Respir J 2012; 40: Suppl. 56, 175

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary arterial hypertension and advanced lung disease in cystic fibrosis patients Source: Eur Respir J 2007; 30: Suppl. 51, 387s Year: 2007 Bosentan treatment in pulmonary arterial hypertension (PAH) associated with interstitial lung diseases (ILDs) Source: Eur Respir J 2006; 28: Suppl. 50, 426s Year: 2006 Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity Source: Eur Respir J 2005; 26: 586-593 Year: 2005 Pulmonary hypertension in patients with interstitial lung disease Source: Annual Congress 2011 - Clinical perspectives in several interstitial diseases Year: 2011 Pulmonary artery dissection (PAD) in a patient with diffuse interstitial lung disease and chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside Year: 2016 A potential role for sildenafil in the management of pulmonary hypertension associated with parenchymal lung disease Source: Eur Respir J 2006; 28: Suppl. 50, 425s Year: 2006 Bosentan and pulmonary hypertension in patients affected by chronic obstructive pulmonary disease Source: Annual Congress 2009 - Pulmonary circulation I Year: 2009 Pulmonary hypertension is common in end-stage sarcoidosis Source: Annual Congress 2005 - Progresses in granolomatous lung disease Year: 2005 Treatment of pulmonary hypertension in chronic obstructive pulmonary disease Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-48-0, page=313 Year: 2006 Tadalafil in idiopathic or heritable pulmonary arterial hypertension compared to pulmonary arterial hypertension associated with connective tissue disease Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Bosentan improves 6-minutes-walk-test in patients with inoperable chronic thrombo-embolic pulmonary hypertension (iCTEPH) Source: Eur Respir J 2005; 26: Suppl. 49, 272s Year: 2005 Pulmonary hypertension in interstitial lung disease Source: Eur Respir J 2008; 31: 1357-1367 Year: 2008 Comparison of pulmonary hypertension (PH) associated to chronic lung disease to other PH groups Source: International Congress 2016 – Pulmonary hypertension in lung disease Year: 2016 Biomarkers in pulmonary hypertension associated to interstitial lung disease Source: Annual Congress 2010 - Pulmonary circulation II Year: 2010 Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children Source: Eur Respir J 2011; 37: 70-77 Year: 2011 Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis Source: Eur Respir J 2012; 40: 93-100 Year: 2012 Pulmonary hypertension due to lung disease Source: International Congress 2017 – Russian Programme 2017 Year: 2017 Inflammatory cell accumulation in pulmonary arteries is associated with systemic inflammation in patients with chronic thromboembolic pulmonary hypertension (CTEPH) Source: Annual Congress 2010 - Pulmonary venous thromboembolic disease Year: 2010 Pulmonary arterial hypertension associated with sarcoidosis (BBS-PAH): mechanisms, hemodynamics and prognosis Source: Eur Respir J 2002; 20: Suppl. 38, 371s Year: 2002 Pulmonary hypertension associated with sarcoidosis Source: Eur Respir Mon 2012; 57: 166-181 Year: 2012